NCT00870103

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

An Evaluation of the Prophylactic Efficacy and Safety of the Administration of the Combination Formulation of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops in Inflammation and Infection Post-cataract Surgery

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Alcon Research · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.

Conditions

• Cataract

Interventions

Type	Name	Description
DRUG	Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops	1 drop every 6 hours into the study eye

Timeline

• Start date: 2008-09-01
• Primary completion: 2009-02-01
• First posted: 2009-03-26
• Last updated: 2010-03-09
• Results posted: 2010-02-15

Locations

1 site across 1 country: United States